by will-heisler | Mar 4, 2026 | Research
On February 12th, the FDA refused to review Moderna’s mRNA-based influenza vaccine. This decision echoed through the life sciences sector, with many industry leaders viewing it as part of a concerning shift in the agency’s stance toward this promising technology. mRNA...
